Taipei Medical University

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Lee Tsung-Ming
------>authors3_c=
------>paper_class1=1
------>Impact_Factor=3.603
------>paper_class3=2
------>paper_class2=1
------>vol=101
------>confirm_bywho=ncchang
------>insert_bywho=ncchang
------>Jurnal_Rank=18.7
------>authors4_c=
------>comm_author=1
------>patent_EDate=None
------>authors5_c=
------>publish_day=15
------>paper_class2Letter=None
------>page2=535
------>medlineContent=
------>unit=E0109
------>insert_date=20080209
------>iam=3
------>update_date=None
------>author=???
------>change_event=4
------>ISSN=
------>authors_c=
------>score=500
------>journal_name=Am J Cardiol., Feb.15, 2008. 101(4): 530-535.//
------>paper_name=Usefulness of C-reactive protein and Interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving Pravastatin.
------>confirm_date=20081205
------>tch_id=075008
------>pmid=18312772
------>page1=530
------>fullAbstract=Inflammation is increased in chronic obstructive pulmonary disease (COPD) and plays a role in exercise intolerance. We investigated whether pravastatin administration is effective in improving exercise capacity in patients with COPD, and whether baseline or serial changes in high-sensitivity C-reactive protein (hs-CRP) over time are associated with corresponding changes in exercise capacity. In a randomized, double-blinded, and parallel design, 125 patients with clinically stable COPD were randomly assigned to receive placebo or pravastatin (40 mg/day) over a period of 6 months. Plasma hs-CRP levels were measured before randomization and during follow-up. Baseline characteristics were similar in the 2 groups. Exercise time remained stable throughout the study in the placebo group. Exercise time increased by 54% from 599 +/- 323 seconds at baseline to 922 +/- 328 seconds at the end (p <0.0001) in pravastatin-treated patients. A decrease in hs-CRP over baseline values was observed in 79% of patients (42 of 53) treated with pravastatin. Pravastatin-treated patients with a greater percent decrease in hs-CRP had a significant improvement in exercise time compared with those without hs-CRP decrease. A significant correlation was found in univariate analysis between decrease of log-transformed hs-CRP and increase of exercise time. Baseline hs-CRP and change of hs-CRP were significantly correlated with exercise time, even after adjustment for lipid profiles and hemodynamics. In conclusion, these data reinforce hs-CRP as a significant surrogate marker in COPD and underscore an important guide to the efficacy of treatment in COPD trials.
------>tmu_sno=None
------>sno=16643
------>authors2=Lin Mei-Shu
------>authors3=Chang Nen-Chung
------>authors4=
------>authors5=
------>authors6=
------>authors6_c=
------>authors=Lee Tsung-Ming
------>delete_flag=0
------>SCI_JNo=None
------>authors2_c=
------>publish_area=0
------>updateTitle=Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin.
------>language=2
------>check_flag=None
------>submit_date=None
------>country=None
------>no=4
------>patent_SDate=None
------>update_bywho=None
------>publish_year=2008
------>submit_flag=None
------>publish_month=1
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z